Drug Trial Radar · NCT07239947
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
99
Planned (sponsor's estimate)
Start
Aug 9, 2025
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Bambusa TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
BBT001Drug
BBT001 will be administered
PlaceboDrug
Placebo will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events following single and multiple administration of BBT001Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
- Number of participants with change in vital sign measurements following treatment administration.Time frame: Part A- Up to Day 141; Part B-Up to Day 169 post first dose administration
- Number of participants with change in serum blood parameters.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
- Number of participants with change in physical examination following treatment administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
- Number of participants with change in 12-lead electrocardiogram (ECG) results measurements following treatment administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical Univesity
Hefei, Anhui, China · Recruiting
The Second Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China · Not yet recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Wuxi Second People's Hospital
Wuxi, Jiangsu, China · Not yet recruiting
Jiangsu University Affiliated Hospital
Zhenjiang, Jiangsu, China · Not yet recruiting
Jiangxi Provincial Dermatology Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Shandong Provincial Hospital for Skin Diseases
Jinan, Shandong, China · Not yet recruiting
Shanghai Dermatology Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.